Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses
Open accessThe DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index; 74 of the 186 sources its claims cite were checked for support.
Abstract
Gene therapy has emerged as a research topic of choice in recent years. The eye in particular is one of few organs of the body for which gene therapy has received Food and Drug Administration approval, and it remains a field of great interest for gene therapy development. However, its associated immune and inflammatory reactions may render the treatment ineffective or harmful, which are of particular concern for the eyes due to their susceptibility to inflammation. The severity of immune and inflammatory reactions depends on the choice of vector and its route of administration. Furthermore, most preclinical and clinical studies have shown that the dose of vectors is correlated with the degree of humoral response and ocular inflammation. The route of administration directly impacts the degree of immune and inflammatory reaction. Subretinal delivery produces a weaker humoral response than the intravitreal route. However, some studies have demonstrated that the subretinal delivery induces a stronger inflammatory reaction. On the other hand, several instances of vision loss due to severe late onset intraocular inflammation were reported in a clinical trial involving intravitreal delivery of viral vectors. When compared with the intravitreal route, suprachoroidal gene delivery has been shown to produce weaker humoral response. However, unlike the subretinal space, the suprachoroidal space is not known to have immune privilege status. Inflammatory reactions following ocular gene therapy are typically mild and most clinical and preclinical studies have shown that they can be controlled with topical, local or systemic steroids. However, severe inflammatory responses may occur and require aggressive management to avoid permanent vision loss. Further investigations are required to elucidate and expand our knowledge of inflammatory reactions, and their optimal management, following ocular gene therapy.
Overview
CoChat Summary
TL;DR
This review summarizes ocular gene therapy vectors, delivery routes, and the immune/inflammatory responses that can limit efficacy or cause harm. It concludes that reactions are usually mild and steroid-responsive, but high-dose intravitreal therapy can cause late-onset sight-threatening inflammation.
Key findings
- Route shapes immune response: subretinal delivery produces a weaker humoral response than intravitreal delivery, while some studies found subretinal delivery induces stronger inflammatory reactions; suprachoroidal delivery has a weaker humoral response than intravitreal but lacks known immune privilege. In the INFINITY trial of intravitreal AAV for diabetic macular edema, patients received high virus dose (N=12), lower virus dose (N=13), or aflibercept (N=9); 3 high-dose patients developed late-onset significant inflammation including panuveitis with hypotony, none in the low-dose or aflibercept groups did, and 2 high-dose patients required mycophenolate.
- Vector dose correlates with inflammation in several trials: Cukras et al. gave AAV8 RS1 intravitreally at 1×10⁹, 1×10¹⁰, and 1×10¹¹ viral particles/eye to nine XLRS patients and found dose-dependent ocular inflammation and dose-dependent serum anti-AAV8 antibodies, with inflammation resolving on oral/topical corticosteroids. Le Meur et al. gave subretinal AAV2 in RPE65-LCA at low (1.22–2×10¹⁰) or high (3.27–4.8×10¹⁰) viral genomes to nine patients; mild anterior chamber protein flare occurred in only 3 patients at the highest dose and resolved after 14 days with local/systemic steroids.
- The FDA-approved voretigene neparvovec trial enrolled 29 pediatric patients older than 3 years with LCA and visual acuity of 20/60 or less, randomized 2:1 to intervention or control; it improved functional vision, had no treatment-related serious adverse events, and mild ocular inflammation occurred in only 2 patients (10%) and resolved.
- AAV seroprevalence and vector constituents matter: about 70% of the normal population has preexisting antibodies against AAV2 versus about 38% against AAV8; antiviral antibodies correlate with minimal or absent gene expression. Timmers et al. found anterior segment inflammation depended on the viral genome, empty capsids did not induce anterior reaction, both full particles and empty capsids induced vitreal inflammation, and antibodies were generated regardless of genome presence.
Methods
- Design: narrative literature review focused on ocular gene therapy and associated immune/inflammatory responses.
- Data: synthesis of preclinical and clinical studies and clinical trials covering viral vectors (adenovirus, AAV, lentivirus), non-viral vectors, ocular disease applications, delivery routes (intravitreal, subretinal, suprachoroidal, electrotransfection), dose/constituent effects, and inflammation management.
- Analysis: qualitative synthesis with referenced tables/figures (Table 1, Table 2, Figure 1); no systematic search strategy, inclusion criteria, or quantitative meta-analysis is described in the provided text.
Limitations
- Paper-stated: further investigations are required to elucidate inflammatory reactions and their optimal management after ocular gene therapy; suprachoroidal delivery needs more study regarding its immune/inflammatory profile; no published data exist on electrotransfection safety in human eyes; small patient numbers may explain why some studies did not detect dose-dependent ocular inflammation; Yiu et al.’s suprachoroidal comparison had a small sample size and was performed in non-human primates.
- Evident from the text: as a narrative review, it does not report a systematic search strategy, formal inclusion/exclusion criteria, risk-of-bias assessment, or quantitative synthesis.
- Evident from the text: evidence is drawn from heterogeneous preclinical and clinical studies, including animal and non-human primate models, with varying vectors, doses, routes, endpoints, and underlying diseases, which limits generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
61 Valid · 11 Not valid · 51 Not checked · 27 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Adenovirus has fallen out of favor due to the resulting robust immune response that causes inflammation and elimination of the transduced cells.”
§ Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses > Introduction > Viral Vectors
What the sources say
- Partly supportedcites [8] Gregory, 2011, Future Virol sourceExperimental — accuracy not yet measured
The Abstract says immune responses increase toxicity and limit transgene expression; it specifically links adaptive responses to elimination of transduced cells. But the section “Attempts to modify AdV vectors to diminish immune responses” says adenoviral vectors are commonly used for gene therapy, so the claim that adenovirus has fallen out of favor overstates the paper’s account. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The presence of antiviral Abs has been correlated with minimal or absent gene expression following gene therapy.”
§ Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses > Introduction > Viral Vectors
What the sources say
- Supportedcites [21] Kotterman, 2015, Gene Ther source
The Results (‘Effect of Pre-Injection Anti-AAV2 Antibodies on Expression’) report that neutralizing antibody titers in monkeys were associated with weak or no transgene expression after intravitreal AAV delivery. The Discussion likewise describes a correlation with weak, decaying, or no expression. The cited finding concerns anti-AAV antibodies in this gene-therapy setting. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, there is still cross-reactivity of anti-AAV Abs against different serotypes.”
§ Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses > Introduction > Viral Vectors
What the sources say
- Supportedcites [21] Kotterman, 2015, Gene Ther source
The Results section, “Cross-Reactivity of Antibodies to Various AAV Serotypes Pre-Infection vs. Post-Infection,” reports that antibody titers against AAV5, AAV8, and AAV9 increased after administration of other serotypes. The Discussion likewise states that administering one of AAV2, AAV8, or AAV9 increased titers against all three. This supports the claimed cross-reactivity, though the paper notes that responses vary by serotype. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“AAVs can be rapidly eliminated by the humoral immune response in patients who have previously been exposed to the virus.”
§ Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses > Introduction > Viral Vectors
What the sources say
- Partly supportedcites [22] Wan, 2015, Mol Med Rep sourceExperimental — accuracy not yet measured
Section 2 (page unavailable) says gene vectors may be rapidly degraded by the immune system, and Section 5 says systemically delivered viral vectors may trigger host antiviral responses. The review does not establish that a humoral response rapidly eliminates AAV specifically in patients previously exposed to the virus. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Yet, the intravitreal vector approach has still shown a different and distinct immune response from subretinal vector delivery.74”
§ Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses > Modes of Delivery of Vector Therapy and Associated Ocular Inflammation > Intravitreal Delivery
What the sources say
- Supportedcites [74] Reichel, 2018, Invest Ophthalmol Vis Sci source
The Conclusions (p. 1) report no significant humoral antibody response after subretinal AAV8 delivery in the studied primates and patients, but a substantial response after intravitreal delivery. The Discussion (p. 5) likewise identifies a higher risk of humoral immune responses with intravitreal injection. The paper supports the comparison specifically for humoral immunity. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
92 more claims · 40 with their cited sources checked
Create a free account to see all 150 claims and every source verdict.
- It may state two separate claims as one. 48
- Probably not a substantial claim. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, the INFINITY trial was halted as several patients developed panuveitis with hypotony and vision loss four to nine months after treatment (Cheng and Punzo, 2022; Ghoraba et al., 2022).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Ghoraba et al., 2022
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“which in turn is less likely to cause excessive inflammatory and immune responses when delivered to this organ [76].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [76]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses > Effect of Vector Dose and Constituents on the Type of Ocular Inflammation > Viral Capsid and Genome
“inflammation in the anterior segment is dependent on the presence of the genome while viral particles with no genome (empty capsids) did not induce an anterior segment reaction.”
§ Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses > Effect of Vector Dose and Constituents on the Type of Ocular Inflammation > Relationship Between Viral Dose and Ocular Inflammation
“No or weak correlation was found between the dose and degree of anterior segment inflammation (which was incited by the capsids only), while a strong correlation was noticed with vitreal inflammation (incited by both the genome and capsid).”
Citations
Cites
Hartong, D. T., Berson, E. L., & Dryja, T. P. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69740-7 · Cited by 2,924
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“Traditional vitrectomy complications such as cataract, IOP rise and retinal tears, as well as subretinal injection-related complications such as a macular hole.(4,87,88) The technique itself requires significant surgical experience.”
BackgroundRussell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952 · cited 10×
“Gene therapy for ocular diseases has already been approved by the United States Food and Drug Administration (FDA) to treat pediatric patients with Leber congenital amaurosis harboring a particular gene deficiency, named RPE65.(4) Multiple promising clinical trials are currently being conducted for many other ocular d…”
BackgroundMethodInfluentialRaper, S. E., Chirmule, N., Lee, F. S., Wivel, N. A., Bagg, A., Gao, G.-P., Wilson, J. M., & Batshaw, M. L. (2003) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.08.016 · Cited by 1,498 · cited 1×
“Severe side effects have been reported using adenovirus, as severe as death of a patient with systemic fever and liver damage in a clinical trial for metabolic disease.(9) Although it does not usually replicate inside hosts, a replication-competent virus can be inadvertently created by combination of adenoviral derive…”
BackgroundBoutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970 · cited 1×
“Therefore, there is a lower percentage of humans with Abs against it (around 38%).(20) The presence of antiviral Abs has been correlated with minimal or absent gene expression following gene therapy.”
BackgroundHauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Non Viral Vectors in Gene Therapy- An Overview
Ramamoorth, M. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/10443.5394 · Cited by 761 · cited 2×
“The non-viral vector approach uses different chemical and physical methods to deliver the therapeutic genetic material.(1) While gene therapy is used to treat inherited diseases with loss of function mutations, it can also be used to treat acquired diseases.”
BackgroundRole of Inflammation in Diabetic Retinopathy
Rübsam, A., Parikh, S., & Fort, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19040942 · Cited by 750
Dalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734 · cited 2×
“Such approach may be beneficial in cases where the targeted cells are not limited only to the macula.(65,66) There are two main limitations of the intravitreal route: the inability to transduce outer retina layers and possible immune and inflammatory reaction.”
BackgroundJacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639
Research works printed but not linked: 7
- Pepose, 1994, Invest Ophthalmol Vis Sci, 35, 2662
- Jiang, 1991, Invest Ophthalmol Vis Sci, 32, 224
- Atherton, 1987, Invest Ophthalmol Vis Sci, 28, 859
- Li, 2008, Mol Vis, 14, 1760
- Wykoff Obotii CC. Intravitreal gene therapy for diabetic macular edema with ADVM-022: first-time data presentation of prospective, randomized phase 2 INFINITY trial [Conference presentation]. American Society of Retina Specialists Annual Scientific Meeting; October 8-12, 2021; 2021; San Antonio, Texas, USA.
- Dante Pieramici O. ADVM-022 intravitreal gene therapy for neovascular AMD: phase 1 OPTIC study [Conference presentation]. American Society of Retina Specialists Annual Scientific Meeting; October 8-12, 2021; 2021; San Antonio, Texas, USA.
- Bucher, 2021, Prog Retin Eye Res, 83, 100915, 10.1016/j.preteyeres.2020.100915 · DOI · Paper page
Cited by
Retinitis Pigmentosa: Current Clinical Management and Emerging Therapies
Nguyen, X., Moekotte, L., Plomp, A. S., Bergen, A. A. B., van Genderen, M. M., & Boon, C. J. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087481 · Cited by 150
“Furthermore, intravitreal and subretinal delivery can induce immune and inflammatory responses, which can typically be managed with steroid therapy, but in rare cases may result in significant ocular inflammation with sight-threatening complications [299].”
BackgroundUpdate on viral gene therapy clinical trials for retinal diseases
Cheng, S.-Y., & Punzo, C. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.159 · Cited by 49
“For a more in-depth review on inflammatory responses seen in ocular gene therapies, we refer the readers to a recently published review on the topic.(139)”
BackgroundMethodEvaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy
Gorovits, B., Azadeh, M., Buchlis, G., Fiscella, M., Harrison, T., Havert, M., Janetzki, S., Jawa, V., Long, B. R., Mahnke, Y. D., et al. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00814-5 · Cited by 52
“These considerations, coupled with the extreme difficulty, if not infeasibility, to acquire ocular immune monitoring samples, would make the detection of a humoral or cellular immune response to an ocular gene therapy of low scientific value, and hence, such assessments may not be required (52, 53).”
BackgroundRowe, L. W., & Ciulla, T. A. (2024) · Genes · doi:10.3390/genes15060720 · Cited by 53
Current developments of gene therapy in human diseases
Liu, F., Li, R., Zhu, Z., Yang, Y., & Lu, F. (2024) · MedComm · doi:10.1002/mco2.645 · Cited by 48
Ocular barriers as a double-edged sword: preventing and facilitating drug delivery to the retina
Wang, L., & Zhang, H. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01231-5 · Cited by 44
“But the mechanisms are poorly understood [113].”
Hosseini-Kharat, M., Bremmell, K. E., Grubor‐Bauk, B., & Prestidge, C. A. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.12.002 · Cited by 37
Toward low-cost gene therapy: mRNA-based therapeutics for treatment of inherited retinal diseases
Antas, P., Carvalho, C., Cabral-Teixeira, J., de Lemos, L., & Seabra, M. C. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.11.009 · Cited by 36
Purdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
Ocular Gene Therapy: An Overview of Viral Vectors, Immune Responses, and Future Directions
Banou, L., Sarrafpour, S., Teng, C. C., & Liu, J. (2024) · The Yale Journal of Biology and Medicine · doi:10.59249/hwid7537 · Cited by 29
Koponen, S., Kokki, E., Tamminen, T., & Ylä-Herttuala, S. (2023) · Frontiers in Drug Delivery · doi:10.3389/fddev.2023.1148795 · Cited by 21
Ford, J. L., Karatza, E., Mody, H. R., Shastri, P. N., Khajehpour, S., Yang, T., Swanson, M., Chao, D. L., & Devineni, D. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3230 · Cited by 25
Ocular Gene Therapy: A Literature Review With Focus on Current Clinical Trials
Wasnik, V. B., & Thool, A. R. (2022) · Cureus · doi:10.7759/cureus.29533 · Cited by 20
“More than 70 genes are found to be concerned with the development of retinitis pigmentosa [18].”
BackgroundSeeing the Future: A Review of Ocular Therapy
Whalen, M., Akula, M., McNamee, S. M., DeAngelis, M. M., & Haider, N. B. (2024) · Bioengineering · doi:10.3390/bioengineering11020179 · Cited by 21
“Certain routes of delivery will elicit different responses and potential risks [7].”
BackgroundInfluentialAbbasi, M., Aghamollaei, H., Vaez, A., Amani, A. M., Kamyab, H., Chelliapan, S., Jamalpour, S., & Zambrano-Dávila, R. (2025) · The Ocular Surface · doi:10.1016/j.jtos.2025.03.004 · Cited by 23
Adeno-associated virus vectors for retinal gene therapy in basic research and clinical studies
Xia, X., & Guo, X. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1310050 · Cited by 25
Lipid nanoparticles for gene therapy in ocular diseases
González, C. C., Saráoz, J. V. M., Roacho-Pérez, J. A., & Olivas-Armendáriz, I. (2023) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-023-00455-1 · Cited by 22
“In recent years, drug delivery systems have been developed to treat diseases associated with the eye [15, 16].”
BackgroundCurrent Advances in Regenerative Strategies for Dry Eye Diseases: A Comprehensive Review
Bhujel, B., Oh, S., Kim, C., Yoon, Y.-J., Chung, H.-S., Ye, E., Lee, H., & Kim, J. Y. (2023) · Bioengineering · doi:10.3390/bioengineering11010039 · Cited by 25
“Further clinical trials are essential to validate its effectiveness [68].”
BackgroundMacLaren, R. E., Audo, I., Fischer, M. D., Huckfeldt, R. M., Lam, B. L., Pennesi, M. E., Sisk, R., Gow, J. A., Li, J., Zhu, K., et al. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.017 · Cited by 15
Looking to the Future of Viral Vectors in Ocular Gene Therapy: Clinical Review
Kharisova, C. B., Kitaeva, K. V., Solovyeva, V. V., Sufianov, A. A., Суфианова, Г. З., Ахметшин, Р. Ф., Bulgar, S. N., & Rizvanov, A. A. (2025) · Biomedicines · doi:10.3390/biomedicines13020365 · Cited by 19
“Although REP1 is expressed ubiquitously, only the retinal pigment epithelium layer is affected in patients with choroideremia, leading to the characteristic clinical phenotype of progressive centripetal degeneration [164].”
InfluentialCruz-Pavlovich, F. J. S., Bolaños-Chang, A. J., Rio-Murillo, X. I. D., Aranda-Preciado, G. A., Razura-Ruiz, E. M., Santos, A., & Navarro‐Partida, J. (2024) · Cells · doi:10.3390/cells13020179 · Cited by 15
“There is an overall tendency towards gene therapy, and although the results seem generally positive, its associated immune and inflammatory reactions may render the treatment ineffective or harmful [243].”
ResultPharmacotherapy and Nutritional Supplements for Neovascular Eye Diseases
Rusciano, D., & Bagnoli, P. (2023) · Medicina · doi:10.3390/medicina59071334 · Cited by 15
“Finally, the potential efficacy of novel therapies, including gene therapy, is under scrutiny, as the eye is one of the few organs of the body for which gene therapy has received FDA approval [43].”
BackgroundGene therapy strategies in ophthalmology—an overview of current developments and future prospects
Krajewska, J. B., & Waszczykowska, A. (2025) · Journal of Applied Genetics · doi:10.1007/s13353-025-00973-5 · Cited by 19
Gene therapy for geographic atrophy in age-related macular degeneration: current insights
Jamil, M. U., & Waheed, N. K. (2024) · Eye · doi:10.1038/s41433-024-03463-w · Cited by 15
“While lentiviruses have traditionally been avoided because of the potential to integrate into the host genome and the subsequent carcinogenic concerns, they do have the ability to carry larger genes than AAV viruses [46].”
Roles of biomaterials in modulating the innate immune response in ocular therapy
Rafiei, M., Chung, J. T., & Chau, Y. (2023) · Frontiers in Drug Delivery · doi:10.3389/fddev.2023.1077253 · Cited by 10
“There are several studies and clinical trials on ocular gene therapy for immunomodulatory approaches using siRNA, miRNA, mRNA, DNA, and plasmid DNA (Ghoraba et al., 2022).”
BackgroundInfluentialSchwartz, M. K., Likhite, S. B., Vetter, T. A., Baird, M., McGovern, V. L., Sierra-Delgado, J. A., Mendel, T., Burghes, A. H. M., & Meyer, K. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.05.016 · Cited by 11
“In addition, AAV vectors achieve limited transduction of photoreceptors after intravitreal injectiondue to thedifficulties of penetrating the inner limiting membrane (ILM), which is a disadvantage of this approach for treatment of outer retinal diseases.(16,18) For this reason, several strategies have been employed to…”
MethodEnhanced immune responses to vaccine antigens in the corneal stroma
Xia, D., Toy, R., Pradhan, P., Hejri, A., Chae, J. J., Grossniklaus, H. E., Cursiefen, C., Roy, K., & Prausnitz, M. R. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.045 · Cited by 10
AlEissa, M. M., Alhawsawi, A. A., Alonazi, R. H., Magharbil, E., Aljahdali, A., ALBalawi, H. B., Alali, N. M., Hameed, S., Abu‐Amero, K. K., & Magliyah, M. (2025) · Genes · doi:10.3390/genes16070847 · Cited by 8
“Reduced seroreactivity and transient immunosuppression regimens have been developed to improve transduction efficiency and enable re-dosing [51].”
InfluentialLim, Y., Campochiaro, P. A., & Green, J. J. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.12.010 · Cited by 10
Aghajanpour, S., Amiriara, H., Ebrahimnejad, P., & Slavcev, R. A. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104359 · Cited by 8
Latest trends & strategies in ocular drug delivery
Kulkarni, N. S., Josowitz, A. D., James, R., Liu, Y., Rayaprolu, B. M., Sagdullaev, B. T., Bhalla, A. S., & Shameem, M. (2025) · Methods · doi:10.1016/j.ymeth.2025.02.003 · Cited by 7
Genetic engineering and the eye
Murphy, R., & Martin, K. R. G. (2024) · Eye · doi:10.1038/s41433-024-03441-2 · Cited by 9
Saboya‐Galindo, P., Mejía‐Salgado, G., Cifuentes‐González, C., Rodríguez-Rodríguez, C. A., Boada-Robayo, L., Méndez-Marulanda, R., Varela, J. S., Riveros-Sierra, L., Gaviria-Carrillo, M., & de‐la‐Torre, A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0307455 · Cited by 9
Assessment of Immune Responses Against AAV Encoded Transgene Products
Gorovits, B., Azadeh, M., Fiscella, M., Harrison, T., Hofer, M., Janetzki, S., Jawa, V., Long, B. R., Lu, Y., Mahnke, Y. D., et al. (2026) · The AAPS Journal · doi:10.1208/s12248-025-01192-w · Cited by 5
“In addition, the subretinal administration route has important implications as the subretinal space is characterized by the presence of a blood-retinal barrier which renders it immune privileged (191).”
Nanotechnological approaches to improve corticosteroids ocular therapy
Formica, M. L., Scerbo, J. M. P., Alfonso, H. G. A., Palmieri, P. T., Ribotta, J., & Palma, S. D. (2024) · Methods · doi:10.1016/j.ymeth.2024.12.008 · Cited by 5
Booler, H. S., Lejeune, T., Turner, O. C., Saravanan, C., Bartoe, J. T., & Bolon, B. N. (2024) · Toxicologic Pathology · doi:10.1177/01926233241307641 · Cited by 6
“20 The first AAV therapeutic to treat ocular disease was voretigene neparvovec-rzyl (Luxturna TM ), an AAV2 gene therapy delivering a working copy of the retinoid isomerohydrolase RPE65 gene to treat Leber’s congenital amaurosis that was approved by the United States Food and Drug Administration…”
Hua, Z., Shen, Y., & Zhou, X. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18030282 · Cited by 5
“In ocular settings, this can reduce editing efficiency and therapeutic benefit, and in some cases may lead to inflammation that threatens visual function [8].”
Cai, S., Liang, X. B., Wu, H., Li, X., & Pu, Q. (2025) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2025.101421 · Cited by 3
Ghoraba, H. H., Haque, M. E., Or, C., et al. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2025.06.005 · Cited by 3
Self-citationGene therapy: New and future treatments for uveitis
Yang, H., Tian, M., & Hou, S. (2024) · Eye & ENT Research · doi:10.1002/eer3.24 · Cited by 4
Progress in Ocular Drug Delivery: Challenges and Constraints
Rupenthal, I. D., & Agarwal, P. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2023_693 · Cited by 6
Haddadzadegan, S., Mehdizdeh, N., Wang, X., Wong, T. T. L., & Miserez, A. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114841 · Cited by 5
Toward Precision Medicine: Gene Therapy Applications in the Management of Uveal Melanoma
Azani, A., Ghassemifar, V., Mehrdad, Z., Saberivand, M., Pour, A. B., Tahmasebi, S., Gharedaghi, H., Sharafi, M., Foroozand, H., Meigoli, M. S. S., et al. (2025) · Cancer Reports · doi:10.1002/cnr2.70425 · Cited by 2
A Practical Guide to Genetic Eye Conditions for Paediatricians
LIN, R.-Y., Ma, A. S., Nash, B. M., McPherson, Z. E., Grigg, J., & Jamieson, R. V. (2025) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.70168 · Cited by 3
Piroozmand, S., Soheili, Z., Latifi‐Navid, H., Samiei, S., Kanavi, M. R., Behrooz, A. B., & Hosseinkhani, S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.141916 · Cited by 2
Gong, X., & Hertle, R. W. (2024) · Life · doi:10.3390/life14111356 · Cited by 4
Clinical and Ocular Inflammatory Inhibitors of Viral-Based Gene Therapy of the Retina
Ohlhausen, M. E., & Conrady, C. D. (2024) · Acta Microbiologica Hellenica · doi:10.3390/amh69030018 · Cited by 2
Krishnapriya, M., Damodaran, A., Joseph, S., Kumar, V., Pillai, G. S., & Nair, S. C. (2023) · Therapeutic Delivery · doi:10.4155/tde-2022-0070 · Cited by 2
Shivgotra, R., Soni, B., Bakrey, H., Kaur, P., & Jain, S. K. (2026) · AAPS PharmSciTech · doi:10.1208/s12249-026-03368-9 · Cited by 2
“Future research should focus on improving clinical evidence, lowering costs, and developing readily accessible platforms for prompt diagnosis”
Long-Term Tolerability and Safety of AAV5 -Id3 Gene Therapy to Eyes
Gupta, S., Kumar, R., Sinha, N. R., Martin, L. M., Sinha, P. R., Fraunfelder, F. W., Hofmann, A. C., Hesemann, N. P., & Mohan, R. R. (2026) · Translational Vision Science & Technology · doi:10.1167/tvst.15.1.38 · Cited by 1
Sassen, S. H., Saßmannshausen, M., Sassen, J., Preising, M. N., Scholz, J. P., Holz, F. G., Lorenz, B., & Herrmann, P. (2025) · Ophthalmologica · doi:10.1159/000549548 · Cited by 2
“Nevertheless, ocular inflammation has been observed as side effect since the first ocular gene therapy trials [19, 20].”
InfluentialOptimizing Tissue Clearing Methods for Improved Imaging of Whole-Mount Retinas
Mutschler, A., Malechka, V. V., Bagaev, N., Baranov, P. Y., & Soucy, J. R. (2025) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2025.110563 · Cited by 1
Immune landscape in children with X-linked retinoschisis
Hsu, Y., Valle, G. S. D., Stanley, S., Lobeck, B., Syrbu, S., Sinkey, C. A., Fortenbach, C. R., Dumitrescu, A. V., & Drack, A. V. (2025) · BMC Immunology · doi:10.1186/s12865-025-00741-4 · Cited by 1
“In ocular gene therapies using viral vectors as delivery vehicles for transgenes, immune response against the viral vectors, DNA, or transgenic protein is a common bottle-neck (reviewed in [8]).”
Ocular toxicity, distribution, and shedding of intravitreal AAV-eqIL-10 in horses
Young, K., Hasegawa, T., Vridhachalam, N., Henderson, N., Salmon, J. H., McCall, T. F., Hirsch, M. L., & Gilger, B. C. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101360 · Cited by 2
Warner, E. F., Vaux, L., Boyd, K., Widdowson, P. S., Binley, K., & Osborne, A. (2024) · Aging and Disease · doi:10.14336/ad.2024.0216-1 · Cited by 2
“However, despite adenovirus-and lentivirus-based gene therapies being well tolerated following clinical administration to the eye [22], there are several hurdles to overcome including short-term expression for the use of adenovirus vectors and limitations in specific retinal cell targeting for the…”
BackgroundRetinitis pigmentosa: klinische Studien der letzten 5 Jahre – eine systematische Literaturrecherche
Perales, C., Moser, E., Badi-Mustafa, T., Wedrich, A., Posch-Pertl, L., Casazza, M., & Strauss, R. W. (2026) · Spektrum der Augenheilkunde · doi:10.1007/s00717-026-00624-y
Artificial intelligence-guided engineering of precision ocular therapeutics
Sayana, R., Wang, S. K., Ting, D. S. W., & Guo, L. Y. (2026) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000001251
Gene therapy clinical trials for inherited eye diseases: The pediatric perspective
Sandali, A., Nikolaidou, A., Gianni, T., Tsoukala, Z., Tsinopoulos, I., & Lamprogiannis, L. P. (2026) · European Journal of Ophthalmology · doi:10.1177/11206721261478166
Bagale, L. R., & Kim, H. J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167096
“Several reviews surveyed gene therapy and genome editing approaches for ocular diseases [145–147].”
Addressing the package: Cell-specific gene delivery using lentiviral vectors
As, S., Warnecke, F. L., Schott, J. J., Morgan, M., & Schambach, A. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.07.031 · Cited by 3
de Oliveira, F. A., Pappas, G. N., Ψαρρού, Μ., Vasilaki, E., Panico, K., Ribeiro, C. A. S., Vamvakaki, M., & Giacomelli, F. C. (2026) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2026.125574
US Retina Specialists’ Preferences for Geographic Atrophy Treatment
Csaky, K. G., Pepio, A. M., Thomas, C., Levitan, B. S., Garg, S., Tran, N., Irony, I., Krucien, N., Doldos, A., & Whitty, J. A. (2026) · Clinical ophthalmology · doi:10.2147/opth.s594882
“Potential GA therapies differ in key characteristics, such as level of efficacy, adverse reaction risks, and injection frequency (eg., ocular gene therapies are being investigated as one-time injections 18–21 ).”
Chen, K.-Y., Chan, H.-C., & Chan, C.-M. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103923 · Cited by 1
“14,15 Adeno-associated virus serotype 2 (AAV2) vectors exhibit strong tropism for retinal cells, particularly photoreceptors and RPE cells.”
Ocular drug delivery in the era of nanomedicine, gene therapy, and digital twins
Choudhary, K., Kumar, A., Kumar, M., Patel, P., & Kurmi, B. D. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108318 · Cited by 1
El-Kalaani, A. M., ten Brink, J. B., Boon, C. J. F., & Koster, C. (2026) · Gene Therapy · doi:10.1038/s41434-026-00601-9
“The natural compartmentalization and immunoprivilege of the eye further reduce the risk of an immune response [24, 29].”
-, R. T., Tiwari, A., & Singh, L. P. (2026) · Journal of Molecular Pathology · doi:10.3390/jmp7010007
Gene therapy in ophthalmology: new prospects
Kharisova, C. B., Kitaeva, K. V., Solovyeva, V. V., Ахметшин, Р. Ф., & Rizvanov, A. A. (2026) · Kazan medical journal · doi:10.17816/kmj677044
Sarma, A. S., & Sharon, D. (2025) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2025.101443 · Cited by 2
Palmgren, V. A. C., Cheng, M. H. Y., Zhang, Y., Carlaw, T., Morin, T., Leung, J., Ross, C. J., Cullis, P. R., & Molday, R. S. (2025) · Gene Therapy · doi:10.1038/s41434-025-00584-z
Willmington, C., Kirby, A., & Murphy, A. (2025) · Health Economics Review · doi:10.1186/s13561-025-00707-7
“The small size, accessibility, confined structure, and immune-privileged status of the eye [74, 75], make it an ideal target for gene therapy, which in turn is less likely to cause excessive inflammatory and immune responses when delivered to this organ [76].”
Optimizing Tissue Clearing Methods for Improved Imaging of Whole-Mount RetinasPreprint
Mutschler, A., Malechka, V. V., Baranov, P. Y., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.14.648787
Therapeutic strategies based on genetic interventions
Baek, R. C., Finn, P. F., & Martini, P. G. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99417-0.00013-6
Vendomèle, J., Chauveau, G. A., Dalkara, D., Galy, A. H. M., & Fisson, S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.30.522324
Metadata
- Authors
- Ghoraba, H. H., Akhavanrezayat, A., Karaca, I., Yavari, N., Lajevardi, S., Hwang, J., Regenold, J., Matsumiya, W., Pham, B., Zaidi, M., Mobasserian, A., DongChau, A. T., Or, C., Yasar, C., Mishra, K., Do, D., & Nguyen, Q. D.
- Affiliations
- Stanford University (US)
- Corresponding author
- Ghoraba, Hashem H
- Akhavanrezayat, Amir
- Karaca, Irmak
- Yavari, Negin
- Lajevardi, Sherin
- Hwang, Jaclyn
- Regenold, Jonathan
- Matsumiya, Wataru
- Pham, Brandon
- Zaidi, Moosa
- Mobasserian, Azadeh
- DongChau, Anthony Toan
- Mishra, Kapil
- Nguyen, Quan Dong
- ORCID
- Venue
- Clinical Ophthalmology
- Publisher
- Informa UK Limited
- Published
- 2022-06
- Volume
- Volume 16
- Pages
- 1753-1771
- ISSN
- 1177-5467 (ISSN-L)
- 1177-5483
- PMC
- PMC9173725
- OpenAlex
- W4281606199
- Cited by
- 76
- References
- 102
- Citations by year
- 2026: 20 · 2025: 19 · 2024: 20 · 2023: 13 · 2022: 4
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical ophthalmology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- National Eye Institute (P30EY026877)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- ocular gene therapy, immune response, ocular inflammation, viral vectors, route of administration, subretinal delivery, intravitreal delivery, humoral immune response, intraocular inflammation, vision loss, immune privilege
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
